2-Bromomescaline
2-Bromomescaline, also known as 2-bromo-3,4,5-trimethoxyphenethylamine, is a putative psychedelic drug of the scaline family and derivative of the phenethylamine hallucinogen mescaline which has an unusual 2-bromo substitution. It is an agonist for serotonin receptors, with a binding affinity of 215 nM at 5-HT1A, 513 nM at 5-HT2A and 379 nM at 5-HT2C, so while it is around 10times more tightly binding than mescaline at 5-HT1A and 5-HT2A receptors, it is over 20times more potent at 5-HT2C. The drug was 5-fold more potent in substituting for LSD than mescaline in rats. It is not known to have been tested in humans. 2-Bromomescaline was first described in the scientific literature, as a chemical intermediate, in 1972. It has been reported as a designer drug, first identified in Austria in January 2023. The drug is not a controlled substance in Canada as of 2025.